Although drugs pass exhaustive controls dedicated to, among other things, detect side effects, their clinical use allows us to find out new details about their effects on the body. This includes associated risks, but also possible additional benefits we did not count on.
Lower risk of dementia. Drugs destined to keep blood sugar levels under control in people with diabetes (such as Ozempic or Zepbound) They can have a positive effectreducing our risk of dementia. Several studies have deepened in this relationship, offering hopeful results in this regard.
Diabetes and dementia. Diabetes is one of the Risk factors that we usually associate with the appearance of dementia, such as age, tobacco, certain genetic factors or cholesterol, among others. Diabetes It is also a risk factor in arterosclerosis and stroke or stroke, which are factors that also contribute to certain forms of dementia.
Knowing this, it can be intuitive to think that drugs that help us keep diabetes at bay can have this type of effects. However, intuition is not enough, so several research groups take time to work to better understand the underlying interactions and be able to strengthen our knowledge about the issue.
Two studies. A few weeks ago, the magazine Jama Neurology He published two independent studies on each other who tried to investigate this issue. Both focused on how drugs aimed at reducing the amount of blood sugar were associated with a lower risk of dementia and cognitive problems among people with type 2 diabetes.
Reviewing the evidence. One of the studies It was based on the systematic review of scientific literature related to the subject, review accompanied by a meta -analysis, a quantitative study of the results compiled through the review. This analysis was carried out from 26 randomized essays among which were added about 165,000 participants.
The team responsible for the study did not find a significant change in the risk of dementia when studying the set of treatments focused on glucose reduction. But he did find that agonists of the peptide receptors similar to type 1 glucagon (LPG-1), the family of compounds to which the semaglutida belongs and therefore Ozempic, were related to a risk of suffering from 45% lower.
One more essay. The second of the studies mentioned focused on two drugs, the agonostas of the GLP-1 receptors (LPG-1st) and the sodium/glucose collection inhibitors 2 (SGLT2is).
The team observed that both the LPG-1ras and the SGLT2is were linked to a lower risk of suffering some forms of dementia such as Alzheimer’s in contrast to other treatments destined for glycemic control.
A key factor. Studying the link between diabetes and dementia can open the way to better understand a disorder as complex as dementia. There is still little that we know about cognitive deterioration associated with age and disorders such as Alzheimer’s, but in increasingly aging societies, finding ways to reduce their weight in the well -being of older people will become unavoidable.
Image | Chemist4u / Steven Hwg
GIPHY App Key not set. Please check settings